Latest Ezetimibe Stories
Drug manufacturer Merck recently sought and earned U.S. Food and Drug Administration approval for a new drug that pairs its own cholesterol-lowering Zetia with a generic version of Lipitor, the blockbuster statin marketed by Pfizer before it lost patent protection in 2011. The Rottenstein Law Group, which represents clients in Lipitor lawsuits, is watching this development closely, noting that studies have established a link between Lipitor and Type 2 diabetes. (PRWEB) May 07, 2013 Drug...
redOrbit Staff & Wire Reports - Your Universe Online Liptruzet, a combination drug developed by Merck that has been found to lower a patient’s low-density lipoprotein (LDL) cholesterol levels, has been approved by the US Food and Drug Administration (FDA). According to MedPage Today Cardiology Editor Chris Kaiser, Liptruzet is a combination of the drugs ezetimibe and atorvastatin and has been approved for the treatment of hyperlipidemia, a condition characterized by abnormally...
SAN FRANCISCO, March 9, 2013 /PRNewswire/ -- Adding extended-release (ER) niacin to statins does not reduce the chances of high risk patients having a heart attack or stroke, Oxford University scientists leading the HPS2-THRIVE study have revealed at the ACC conference in San Francisco today. In addition, the researchers report that the use of ER niacin causes a significant number of different types of serious side effect. Some of these side effects were already known...
The largest randomized study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side-effects when it is combined with statin treatment. Results from the HPS2-THRIVE study (Heart Protection Study 2 – Treatment of HDL to Reduce the Incidence of Vascular Events), including the reasons patients stopped the study treatment, are published online today (Wednesday) in the European Heart Journal. Niacin has...
NEW YORK, Feb. 14, 2013 /PRNewswire/ -- Today Labaton Sucharow LLP, along with its co-counsel, announced that it reached a $473 million settlement in In re Schering-Plough Corporation / ENHANCE Securities Litigation. The recovery is the largest securities class action settlement ever against a pharmaceutical company, among the top 25 securities class action settlements of all time, and among the ten largest recoveries ever in a securities class action that did not involve a defendant...
April Flowers for redOrbit.com - Your Universe Online Statins are the first line of defense for many people with high cholesterol. For some patients, however, statins do not reduce their low-density lipoprotein cholesterol (LDL) levels. LDL is considered the "bad cholesterol." Some patients' bodies are unable to tolerate statins, or they simply do not respond sufficiently to the medication. New research from Brigham and Women's Hospital, presented at the 2012 American Heart Association...
THOUSAND OAKS, Calif., Nov. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that treatment with AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in low density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, by up to 56 percent in patients with heterozygous familial hypercholesterolemia (HeFH) in the Phase 2 RUTHERFORD study. AMG 145 is an investigational fully human monoclonal antibody directed against PCSK9, a...
PARIS and TARRYTOWN, N.Y., Oct. 31, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine. The study enrolled patients with primary hypercholesterolemia with elevated LDL-C (greater than or equal to 100 mg/dL) who were on a...
PARIS and TARRYTOWN, New York, July 20, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment. SAR236553/REGN727 is a potential first-in-class, subcutaneously administered, fully-human antibody that lowers low-density lipoprotein (LDL) cholesterol by targeting PCSK9 (proprotein convertase...
FRAMINGHAM, Mass., May 30, 2012 /PRNewswire/ -- Boston Heart Diagnostics (BHD) announced today the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation. This adds to the company's IP portfolio and suite of cardiovascular disease (CVD)-focused tests that are designed to improve outcomes for patients and save health dollars by tailoring a therapeutic regimen to the patient's...
